The Proteome of Primary Prostate Cancer

European Urology

Volumn 69, Issue 5, 2016, Pages 942-952

  Iglesias Gato, Diego ^a,b   Wikström, Pernilla ^c   Tyanova, Stefka ^d   Lavallee, Charlotte ^a,b   Thysell, Elin ^c   Carlsson, Jessica ^e   Hägglöf, Christina ^c   Cox, Jürgen ^d   Andrén, Ove ^e   Stattin, Pär ^c   Egevad, Lars ^f   Widmark, Anders ^c   Bjartell, Anders ^g   Collins, Colin C ^h   Bergh, Anders ^c   Geiger, Tamar ⁱ   Mann, Matthias ^a,d   Flores Morales, Amilcar ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^c UMEÅ UNIVERSITY   (Sweden)

^d MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^e ÖREBRO UNIVERSITY   (Sweden)

^f KAROLINSKA INSTITUTE   (Sweden)

^g LUND UNIVERSITY   (Sweden)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁱ TEL AVIV UNIVERSITY   (Israel)

Author keywords

Formalin fixed paraffin embedded; Proneuropeptide Y; Prostate cancer; Quantitative proteomics; Watchful waiting

Indexed keywords

CARNITINE PALMITOYLTRANSFERASE 2; COATOMER PROTEIN COMPLEX SUBUNIT ALPHA; FATTY ACID; FATTY ACID TRANSPORTER; MITOCHONDRIAL PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; NEUROPEPTIDE; PRONEUROPEPTIDE Y; PROTEOME; STRESS ACTIVATED PROTEIN KINASE 1; TRANSCRIPTION FACTOR ERG; UNCLASSIFIED DRUG; ERG PROTEIN, HUMAN; NEUROPEPTIDE Y; PROTEIN PRECURSOR; TUMOR MARKER;

ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURGERY; CELL PROLIFERATION; CONTROLLED STUDY; FATTY ACID SYNTHESIS; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MASS SPECTROMETRY; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN SYNTHESIS; PROTEOMICS; QUANTITATIVE ANALYSIS; CANCER GRADING; DISEASE EXACERBATION; METABOLISM; PATHOLOGY; PROGNOSIS; PROSTATE; PROSTATE TUMOR; WATCHFUL WAITING;

BIOMARKERS, TUMOR; DISEASE PROGRESSION; HUMANS; MALE; MASS SPECTROMETRY; MITOCHONDRIAL PROTEINS; NEOPLASM GRADING; NEUROPEPTIDE Y; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN PRECURSORS; PROTEOME; TRANSCRIPTIONAL REGULATOR ERG; WATCHFUL WAITING;

EID: 84949309957     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2015.10.053     Document Type: Article

References (50)

1. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics, 2014 CA Cancer J Clin 64 2014 9 29
2. J.R. Rider, F. Sandin, O. Andren, P. Wiklund, J. Hugosson, and P. Stattin Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study Eur Urol 63 2013 88 96
3. S. Loeb, A. Berglund, and P. Stattin Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer J Urol 190 2013 1742 1749
4. C.E. Barbieri, S.C. Baca, M.S. Lawrence, and et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer Nat Genet 44 2012 685 689
5. C.S. Grasso, Y.M. Wu, D.R. Robinson, and et al. The mutational landscape of lethal castration-resistant prostate cancer Nature 487 2012 239 243
6. B.S. Taylor, N. Schultz, H. Hieronymus, and et al. Integrative genomic profiling of human prostate cancer Cancer Cell 18 2010 11 22
7. A.W. Wyatt, F. Mo, K. Wang, and et al. Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer Genome Biol 15 2014 426
8. N. Nagaraj, J.R. Wisniewski, T. Geiger, and et al. Deep proteome and transcriptome mapping of a human cancer cell line Mol Syst Biol 7 2011 548
9. B. Schwanhausser, D. Busse, N. Li, and et al. Global quantification of mammalian gene expression control Nature 473 2011 337 342
10. B. Zhang, J. Wang, X. Wang, and et al. Proteogenomic characterization of human colon and rectal cancer Nature 513 2014 382 387
11. M. Mann, N.A. Kulak, N. Nagaraj, and J. Cox The coming age of complete, accurate, and ubiquitous proteomes Mol Cell 49 2013 583 590
12. T. Geiger, J. Cox, P. Ostasiewicz, J.R. Wisniewski, and M. Mann Super-SILAC mix for quantitative proteomics of human tumor tissue Nat Methods 7 2010 383 385
13. P. Ostasiewicz, D.F. Zielinska, M. Mann, and J.R. Wisniewski Proteome, phosphoproteome, and N-glycoproteome are quantitatively preserved in formalin-fixed paraffin-embedded tissue and analyzable by high-resolution mass spectrometry J Proteome Res 9 2010 3688 3700
14. J.V. Olsen, J.C. Schwartz, J. Griep-Raming, and et al. A dual pressure linear ion trap Orbitrap instrument with very high sequencing speed Mol Cell Proteomics 8 2009 2759 2769
15. J. Cox, and M. Mann MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification Nat Biotechnol 26 2008 1367 1372
16. J. Cox, N. Neuhauser, A. Michalski, R.A. Scheltema, J.V. Olsen, and M. Mann Andromeda: a peptide search engine integrated into the MaxQuant environment J Proteome Res 10 2011 1794 1805
17. A. Josefsson, P. Wikstrom, L. Egevad, and et al. Low endoglin vascular density and Ki67 index in Gleason score 6 tumours may identify prostate cancer patients suitable for surveillance Scand J Urol Nephrol 46 2012 247 257
18. O. Andren, K. Fall, L. Franzen, S.O. Andersson, J.E. Johansson, and M.A. Rubin How well does the Gleason score predict prostate cancer death?. A 20-year followup of a population based cohort in Sweden J Urol 175 2006 1337 1340
19. K. Ahlqvist, K. Saamarthy, A.S. Syed Khaja, A. Bjartell, and R. Massoumi Expression of Id proteins is regulated by the Bcl-3 proto-oncogene in prostate cancer Oncogene 32 2013 1601 1608
20. D. Whitaker-Menezes, U.E. Martinez-Outschoorn, N. Flomenberg, and et al. Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue Cell Cycle 10 2011 4047 4064
21. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
22. Y. Kobayashi, D.M. Absher, Z.G. Gulzar, and et al. DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer Genome Res 21 2011 1017 1027
23. J.B. Helms, and J.E. Rothman Inhibition by brefeldin A of a Golgi membrane enzyme that catalyses exchange of guanine nucleotide bound to ARF Nature 360 1992 352 354
24. J.R. Wisniewski, P. Ostasiewicz, K. Dus, D.F. Zielinska, F. Gnad, and M. Mann Extensive quantitative remodeling of the proteome between normal colon tissue and adenocarcinoma Mol Syst Biol 8 2012 611
25. J. Lindberg, I.G. Mills, D. Klevebring, and et al. The mitochondrial and autosomal mutation landscapes of prostate cancer Eur Urol 63 2013 702 708
26. L.C. Costello, and R.B. Franklin Prostate epithelial cells utilize glucose and aspartate as the carbon sources for net citrate production Prostate 15 1989 335 342
27. A. Leiblich, S.S. Cross, J.W. Catto, and et al. Lactate dehydrogenase-B is silenced by promoter hypermethylation in human prostate cancer Oncogene 25 2006 2953 2960
28. L. Egevad, T. Granfors, L. Karlberg, A. Bergh, and P. Stattin Percent Gleason grade 4/5 as prognostic factor in prostate cancer diagnosed at transurethral resection J Urol 168 2002 509 513
29. J.R. Stark, S. Perner, M.J. Stampfer, and et al. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol 27 2009 3459 3464
30. D.G. Bostwick, A. Pacelli, M. Blute, P. Roche, and G.P. Murphy Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases Cancer 82 1998 2256 2261
31. C. Hagglof, and A. Bergh The stroma-a key regulator in prostate function and malignancy Cancers (Basel) 4 2012 531 548
32. K.K. Rasiah, J.G. Kench, M. Gardiner-Garden, and et al. Aberrant neuropeptide Y and macrophage inhibitory cytokine-1 expression are early events in prostate cancer development and are associated with poor prognosis Cancer Epidemiol Biomarkers Prev 15 2006 711 716
33. L. Funkelstein, T. Toneff, S.R. Hwang, T. Reinheckel, C. Peters, and V. Hook Cathepsin L participates in the production of neuropeptide Y in secretory vesicles, demonstrated by protease gene knockout and expression J Neurochem 106 2008 384 391
34. P. Massoner, K.G. Kugler, K. Unterberger, and et al. Characterization of transcriptional changes in ERG rearrangement-positive prostate cancer identifies the regulation of metabolic sensors such as neuropeptide Y PloS One 8 2013 e55207
35. C. Hagglof, P. Hammarsten, K. Stromvall, and et al. TMPRSS2-ERG expression predicts prostate cancer survival and associates with stromal biomarkers PloS One 9 2014 e86824
36. S.H. Tan, B. Furusato, X. Fang, and et al. Evaluation of ERG responsive proteome in prostate cancer Prostate 74 2014 70 89
37. M. Wilhelm, J. Schlegl, H. Hahne, and et al. Mass-spectrometry-based draft of the human proteome Nature 509 2014 582 587
38. S.A. Tomlins, R. Mehra, D.R. Rhodes, and et al. Integrative molecular concept modeling of prostate cancer progression Nat Genet 39 2007 41 51
39. Y.C. Chuan, D. Iglesias-Gato, L. Fernandez-Perez, and et al. Ezrin mediates c-Myc actions in prostate cancer cell invasion Oncogene 29 2010 1531 1542
40. J.B. Tennakoon, Y. Shi, J.J. Han, and et al. Androgens regulate prostate cancer cell growth via an AMPK-PGC-1alpha-mediated metabolic switch Oncogene 33 2014 5251 5261
41. A.S. Rambold, and J. Lippincott-Schwartz Mechanisms of mitochondria and autophagy crosstalk Cell Cycle 10 2011 4032 4038
42. P. Mao, K. Nakao, and A. Angrist Human prostatic carcinoma: an electron microscope study Cancer Res 26 1966 955 973
43. B. Movsas, J.D. Chapman, R.E. Greenberg, and et al. Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age: an Eppendorf pO(2) study Cancer 89 2000 2018 2024
44. D. Margel, D.R. Urbach, L.L. Lipscombe, and et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes J Clin Oncol 31 2013 3069 3075
45. L. Egevad, T. Granfors, L. Karlberg, A. Bergh, and P. Stattin Prognostic value of the Gleason score in prostate cancer BJU Int 89 2002 538 542
46. K. Ueda, A. Tatsuguchi, N. Saichi, and et al. Plasma low-molecular-weight proteome profiling identified neuropeptide-Y as a prostate cancer biomarker polypeptide J Proteome Res 12 2013 4497 4506
47. O. Nagakawa, M. Ogasawara, J. Murata, H. Fuse, and I. Saiki Effect of prostatic neuropeptides on migration of prostate cancer cell lines Int J Urol 8 2001 65 70
48. M. Ruscica, E. Dozio, S. Boghossian, and et al. Activation of the Y1 receptor by neuropeptide Y regulates the growth of prostate cancer cells Endocrinology 147 2006 1466 1473
49. C.D. Allen, B. Waser, M. Korner, J.C. Reubi, S. Lee, and C. Rivier Neuropeptide Y acts within the rat testis to inhibit testosterone secretion Neuropeptides 45 2011 55 61
50. J. Kitlinska, K. Abe, L. Kuo, and et al. Differential effects of neuropeptide Y on the growth and vascularization of neural crest-derived tumors Cancer Res 65 2005 1719 1728